# Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).

> **NCT03526861** · PHASE3 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 301 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Tralokinumab
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03526861
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-19
- **Primary completion:** 2020-04-15
- **Final completion:** 2021-03-16
- **Target enrollment:** 301 (ACTUAL)
- **Last updated:** 2025-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03526861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03526861, "Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03526861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*